Current Trials Open to Accrual
Breast Cancer
As of 6/17/2016

**Newly Diagnosed/Nonmetastatic**

**Neoadjuvant**

*The HER-ITAAGe Project:* Helping Educate about Risk: Improving Access and Awareness of Genetic Testing (UIC IRB 2014-0610)

*BRE_BIO-02:* Breast Tissue Biospecimen Collection Protocol (UIC IRB 2014-1078)

**Adjuvant**

*ACOSOG Z11102:* Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)

*SWOG S1207:* Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER/NEU Negative Breast Cancer (UIC IRB# 2013-0232)

*NSABP B-55:* A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (UIC IRB 2014-0071)

**Metastatic**

*AbbVie M12-914:* Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (UIC IRB# 2014-0718)
**CLEE011E2301 (MONALEESA-7):** A Phase III Randomized, Double-Blind, Placebo-Controlled Study of LEE011 or Placebo in Combination with Tamoxifen and Goserelin or Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (UIC IRB#2015-0039)

**ACCRU RU011201I:** A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First or Second-line Therapy for Locally Recurrent or Metastatic Breast Cancer (UIC IRB #2014-0671)

**NRG-BR002:** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

**Phase 1 Studies**

**STM-02:** Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGFR (UIC IRB# 2013-0655)

**STM-03:** Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid Tumors (UIC IRB #2015-0057)

For screening potential patients, please call:

MEREDITH RUSSELL, CCRP
Phone: 5-5112
In-House Pager: 136-5317
Email: mrussel3@uic.edu